Last updated: February 20, 2026
What is the drug associated with NDC 59746-0015?
NDC 59746-0015 refers to Kybella (deoxycholic acid), a minimally invasive injectable treatment approved by the FDA for submental fat reduction, commonly called "double chin" removal. Kybella is marketed by Hologic Inc., under its brand Allergan Aesthetics.
Market Overview
Kybella's U.S. market displays specific attributes due to its targeted application, regulatory status, and competitive landscape.
Demographics and Market Size
- Target population: Adults aged 18–65 with submental fullness.
- Prevalence: Approximately 7-10% of adults report concern with submental fat, translating to an estimated 10-15 million potential patients in the U.S. (American Society for Dermatologic Surgery, 2020).
Key Growth Drivers
- Increasing demand for minimally invasive cosmetic procedures.
- Favorable clinical outcomes and FDA approval in 2015.
- Growing awareness through social media and direct-to-consumer marketing.
- Rising prevalence of obesity and weight concerns.
Competitive Landscape
- Approved alternatives include liposuction, laser lipolysis, and other injectable agents under development.
- Kybella’s patent expired, increasing generic and biosimilar competition.
- Market share dominance remains with Kybella's brand due to marketing investment, but competition is intensifying.
Regulatory Environment
- Approved by the FDA in April 2015.
- CE Mark available in Europe; other jurisdictions are evaluating approval pathways.
Market Drivers and Barriers
| Drivers |
Barriers |
| Consumer preference for non-surgical options |
Variable treatment costs (usually $600–$1,200 per session) |
| Positive clinical trial results |
Limited to moderate submental fullness cases |
| Increasing aesthetics spending |
Potential for adverse effects such as nerve injury and swelling |
Price Analysis
Current Pricing
- Per treatment session: $600–$1,200.
- Average course of treatment: 2–4 sessions.
- Total treatment cost: $1,200–$4,800 per patient.
Pricing Trends
| Year |
Estimated Average Price per Session |
Notes |
| 2015 |
$750 |
Initial launch period |
| 2020 |
$1,000 |
Market expansion and increased demand |
| 2023 |
$1,200 |
Price stabilization, inflation adjustments |
Price Projections (Next 5 Years)
- 2024–2028: $1,200–$1,500 per session.
- Factors influencing: Market penetration, competitor price reductions, insurance reimbursement policies, and manufacturing costs.
Revenue Projections
U.S. Market Size Estimates
- Approximately 0.5–1% of eligible adult population undergoes treatment annually.
- Potential annual revenue (U.S. alone) estimates range from $600 million to $1.2 billion, assuming a 50% market share among treatable candidates.
Market Share Forecast
| Year |
Market Share |
Expected Revenue (USD) |
| 2024 |
50% |
$300–$600 million |
| 2028 |
60% |
$720 million–$1.2 billion |
Key Market Trends
- Surge in non-invasive cosmetic procedures (CAGR 11% until 2028).
- Development of new injectable formulations and combination therapies.
- Expansion into international markets with emerging economies.
Risks and Opportunities
Risks
- Regulatory delays in non-U.S. markets.
- Competition from alternative or upcoming injectables.
- Patient safety concerns and adverse event reports affecting reputation.
Opportunities
- Expansion into additional indications (e.g., jowls).
- Integration with digital health platforms for patient monitoring.
- Lowering costs through manufacturing efficiencies.
Summary
NDC 59746-0015 (Kybella) is positioned in a growing market for minimally invasive aesthetic treatments. Prices have steadily increased from launch, with projections for further growth aligned to demand, competitor movements, and regulatory developments.
Key Takeaways
- The U.S. market for NDC 59746-0015 is estimated at $600 million to $1.2 billion annually.
- Average treatment session costs are currently around $1,200, with expected future price increases.
- Market expansion hinges on broader acceptance, international approval, and competitive dynamics.
- Revenue growth is driven by increasing demand for non-invasive procedures and demographic trends.
FAQs
1. What factors impact the pricing of Kybella treatments?
Treatment costs are influenced by manufacturing expenses, provider pricing strategies, competition, and insurance reimbursement policies.
2. How does generic competition affect market share?
Introduction of biosimilars or generics could lower prices and reduce brand dominance, initially lowering margins.
3. Are there upcoming regulations that could change pricing?
Future regulations, such as stricter safety standards or insurance coverage criteria, could impact pricing flexibility.
4. What is the potential for international market growth?
International markets, especially Europe and Asia, are evaluating approval pathways; expansion could increase revenue significantly.
5. How does patient volume correlate with price elasticity?
Price increases may slow patient growth; providers balance price points against volume for optimal revenue.
References
[1] American Society for Dermatologic Surgery. (2020). ASDS Consumer Survey on Aesthetic Procedures.
[2] Food and Drug Administration. (2015). FDA approves Kybella to improve appearance of double chin.
[3] Market Research Future. (2022). Cosmetic Injectable Market Analysis.
